Bard (C.R.) Inc. (NY: BCR)
139.49 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(BCR) Community Analysis from
April 20, 2014
Another great stock has raised its dividend. This time it’s C.R. Bard ( $ BCR). Here’s a description from Hoovers. C. R. Bard is no upstart in [...]
(Benzinga, 10/21/10)
CR Bard Inc. (NYSE: BCR) reports Q3 earnings of $1.43 versus consensus of $1.40. CR Bard Inc. reports revenues of $678.4 million versus consensus of $686.77 million. Excluding the impact of foreign exchange, third quarter 2010 net...(read more)
(Benzinga, 10/22/10)
C.R. Bard, Inc. (NYSE: BCR) reported 3Q results with slightly lower sales and EPS of $1.43 versus Morgan Keegan's $1.39 estimate. “Given the challenging global health care markets, we view Bard's results favorably,” Morgan Keegan...(read more)
C.R. Bard (BCR) Company Overview

C.R. Bard (NYSE: BCR) manufactures medical devices such as stents and catheters. The company leads in market share in nearly all its markets.

Oncology was one of Bard's fastest growing therapeutic areas, with over 19% sales growth. Cancer is the second leading cause of death in developed countries and the third worldwide, and people spend billions of dollars annually on cancer research and treatment.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here